Merck's discount wins NICE nod for Keytruda; FDA flags user-error worries with Purdue's new painkiller;

> Merck & Co.'s ($MRK) new cancer immunotherapy Keytruda won backing from the U.K.'s cost-effectiveness watchdogs after offering an unspecified discount. Report

> FDA staff reviewers flagged likely errors in administering Purdue Pharma's new fast-acting oxycodone painkiller, saying taking the drug with food can interfere with its effectiveness. Report

> Canadian regulators cleared Recordati's rare disease drug Carbaglu for marketing, as a treatment for hyperammonemia. Report

> Two leading U.S. physicians' organizations say proposed megamergers in the health insurance business will be anti-competitive. Report

And Finally... U.K. life sciences groups, including pharma companies, urged the government not to cut research funding, citing the economic benefits of R&D work. Report

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.